Immunosuppressive treatment for idiopathic nephrotic syndrome with corticosteroids and cyclophosphamide. Factors associated with a favourable outcome

Clinical Drug Investigation

Volumn 16, Issue 3, 1998, Pages 211-218

  Pirisi, Mario ^a   Faedda, Rossana ^b   Satta, Andrea ^b   Bartoli, Ettore ^a  

^a Ospedale di Careggi   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISONE;

ADULT; ARTICLE; BLADDER CANCER; BONE ATROPHY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFERTILITY; INTRAVENOUS DRUG ADMINISTRATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; REMISSION; TREATMENT OUTCOME;

EID: 0031671028     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816030-00005     Document Type: Article

References (32)

1. Glassock RJ, Adler SG, Ward HJ, et al. Primary glomerular diseases. In: Brenner BM, Rector Jr FC, editors. The Kidney. 4th ed. Philadelphia: Saunders, 1991; 1182-279
2. Diamond JR, Karnovski MJ. Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 1988; 33: 917-24
3. Wilson CB. The renal response 10 immunologic injury. In: Brenner BM, Rector Jr FC, editors. The Kidney. 4th ed. Philadelphia: Saunders, 1991: 1062-181
4. Schena FP, Cameron JS. Treatment of proteinuric idiopathic glomerulonephritides in adults: a retrospective survey. Am J Med 1988; 85: 315-26
5. Churg J, Habib R, White RHR. Pathology of the nephrotic syndrome in children. A report for the International Study of Kidney Disease in Children. Lancet 1970; 1: 1299-302
6. International Study of Kidney Disease in Children. Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. Kidney Int 1981; 20: 765-71
7. Lewis EJ. Chlorambucil for childhood nephrosis. A word of caution. N Engl J Med 1980; 302: 963-4
8. Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med 1998; 338: 1202-11
9. Faedda R, Satta A, Bosincu L, et al. Immune suppressive treatment of membranous glomerulonephritis. J Nephrol 1995; 8: 107-12
10. Faedda R, Satta A, Tanda F, et al. Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron 1994; 67: 59-65
11. Faedda R, Satta A, Tanda F, et al. Immune suppressive treatment of nephrotic syndrome due to mesangial lesions. Clin Nephrol 1996; 46: 237-44
12. Alexopoulos E, Sakellariou G, Memmos D, et al. Cyclophosphamide provides no additional benefit to steroid treatment in the treatment of idiopathic membranous nephropathy. Am J Kidney Dis 1993; 21: 497-503
13. Bruns FJ, Adler S, Fraley DS, et al. Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone. Ann Intern Med 1991; 114: 725-30
14. Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993; 329: 85-9
15. Faedda R, Palomba D, Satta A, et al. Immunosuppressive treatment of the glomerulonephritis of systemic lupus. Clin Nephrol 1995; 44: 367-75
16. Earley LE, Havel RJ, Hopper Jr J, et al. Nephrotic syndrome. Calif Med 1971; 115: 23-41
17. Samrook P, Birmingham RN, Kelly P, et al. Prevention of corticosteroid osteoporosis. N Engl J Med 1993; 328: 1747-52
18. Boumpas DT, Austin HA, Vaughan EM, et al. Risk for substained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366-9
19. Masala A, Faedda R, Alagna S, et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 1997; 126: 292-5
20. Levinc EG, Bloomfield CD. Leukemias and myelodisplastic syndromes secondary to drug, radiation and environmental exposure. Semin Oncol 1992; 19: 47-84
21. Pedersen-Bjergaard J, Specht L, Larsen SO, et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Lancet 1987; 11: 83-8
22. Pedersen-Bjergaard J, Ersboll J, Mygind Sorensen H, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin lymphomas. Ann Int Med 1985; 103: 195-200
23. Zarrabi MH. Association of non-Hodgkin's lymphoma and second neoplasms. Semin Oncol 1990; 17: 120-32
24. Lee JC, Yamauchi H, Hopper Jr J. The association of cancer and the nephrotic syndrome. Ann Intern Med 1966; 64: 41-51
25. Faedda R, Pirisi M, Satta A, et al. Immunosuppressive treatment of Berger's disease. Clin Pharmacol Ther 1996; 60: 561-7
26. Faedda R, Pirisi M, Satta A, et al. Regression of Henoch-Schönlein disease with intensive immunosuppressive treatment. Clin Pharmacol Ther 1996; 60: 567-81
27. Honkanen E, von Willebrand E, Teppo AM, et al. Adhesion molecules and urinary tumor necrosis factor-alpha in idiopathic membranous glomerulonephritis. Kidney Int 1998; 53: 909-17
28. Fujimoto S, Yamamoto Y, Hisanaga S, et al. Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse. Am J Kidney Dis 1991; 17: 687-92
29. Curry RC, Roberts WC. Status of the coronary arteries in the nephrotic syndrome. Analysis of 20 necropsy patients aged 15 to 35 years to determine if coronary atherosclerosis is accelerated. Am J Med 1977; 63: 183-92
30. Sheil AGR, Flavel S, Disney APS, et al. Cancer in dialysis and transplant patients. Transplant Proc 1985; 17: 195-8
31. Penn I. Neoplastic consequences of transplantation and chemotherapy. Cancer Det Prev 1987; 9 Suppl. 1: 149-57
32. Abbate M, Remuzzi G. Innovative strategies for pharmacological intervention in immune damage to the kidney. Nephrol Dial Transplant 1995; 10: 1131-6